Combining PI3K/AKT and MAPK/ERK inhibitors to combat PTEN-driven resistance, profiling PTEN status for personalized treatment selection, and advancing precision medicine by leveraging PTEN/MAPK insights for more effective cancer therapy. Here, AKT1 is linked to cancer.